Bortezomib (PS-341)

Catalog No.S1013

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Cited by 142 publications:

20 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF-7M3PSfWN6fG:2b4jpZ{BCe3OjeR?=NF:1SVA2OCEQvF2=MkTWOFghcA>?Mmr3SG1UVw>?MXjLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUmlMnXUNVA1QTl4NEO=
OVCA 429MXPGeY5kfGmxbjDBd5NigQ>?NIG3[og{ODBibl2=M3TUVVQ5KGh?MX\EUXNQNF3kRVlFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>NEnvTpQyODl7OUe2Oi=>
RPMI8226M2r5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XvWFExOCCwTR?=Mn3EOFghcA>?M2[wNmROW09?MnLmTWM2OD1|MDDuUS=>MVuxNVMxPjR6OR?=
Dox40MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWqxNFAhdk1?NGrWUGg1QCCqMoT4SG1UVw>?NFTabo1KSzVyPUSwJI5ONXLHWpM4OTF|ME[0PFk>
MR20MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nUWVExOCCwTR?=MUK0PEBpM17rT2ROW09?NYDGWXFbUUN3ME2yNEBvVQ>?MmXPNVE{ODZ2OEm=
LR5MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XOV|ExOCCwTR?=NGPHcXQ1QCCqM3HRVWROW09?NWDzWG9LUUN3ME2yNEBvVQ>?NYnMUm1VOTF|ME[0PFk>
U266NFfvWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLBTGh{OTByIH7NMnvCOFghcA>?M4XpUmROW09?NXHnWnZHUUN3ME2zJI5OM{\lZVEyOzB4NEi5
IM-9NF2wW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[xNFAhdk1?M3THeVQ5KGh?M1j6UmROW09?M1;WOWlEPTB;NjDuUS=>NGf1XmYyOTNyNkS4PS=>
Hs SultanMnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWqyRlBtOTByIH7NNX7MOFR2PDhiaB?=M4fQNGROW09?NYfwd5lOUUN3ME2yNEBvVQ>?NFPFemUyOTNyNkS4PS=>
PAM-LY2NH;NTXZHfW6ldHnvckBCe3OjeR?=M2mzeVExOCCwTR?=NEP2PYMyOiCqMX;EUXNQM{\ieGlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;uNH;YSYgyOTN3MEmxNy=>
PAM 212NEDsVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2GxTlExOCCwTR?=NVPoUGhvPzJiaB?=M{jxOWROW09?NIHHSYNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=NVHYOW83OTF|NUC5NVM>
PAM-LY2MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX6xNFAhdk1?MXO3NkBpMlzoSG1UVw>?MWnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?Mo\4NVE{PTB7MUO=
B4B8MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVT5SJh7OTByIH7NMUm3NkBpNYnr[49LTE2VTx?=Moe5TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?MWixNVM2ODlzMx?=
B7E3MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDoWY0yODBibl2=MlfPO|IhcA>?NVW0NnFKTE2VTx?=MkH0TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?MV:xNVM2ODlzMx?=
UM-SCC-9NITHcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHf1bpYyODBibl2=MV[3NkBpNELGZ2pFVVORNVG4WoJFUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=M3OwdVEyOzVyOUGz
UM-SCC-11BNVrqXW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWGxNFAhdk1?NXnqeI9pPzJiaB?=NWOx[IxOTE2VTx?=M3TwdWlvcGmkaYTzJINmdGxidnnhZoltcXS7M2rrTFEyOzVyOUGz
H460MnzRSpVv[3Srb36gRZN{[Xl?MkfmNVAh|ryPMofzNlQhcA>?MlPNSG1UVw>?M2XRXGlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R?Mkj6NVI1QTJzMUe=
U266NUSw[JV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\iOJpqPTByIH7nM41tM{X0U|Q5KGh?NHTkPXdFVVORM362OGlvcGmkaYTzJINmdGxiZ4Lve5RpMkWxNVI3OzF4MUm=
ARH77MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDIOVAxKG6pL33sNV7DUlFtPDhiaB?=NWPHWpRzTE2VTx?=NUTDU4dIUW6qaXLpeJMh[2WubDDndo94fGh?MX2xNlY{OTZzOR?=
WAD-1MlrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWe1NFAhdmdxbXy=NVfuflE1PDhiaB?=NIfTNYdFVVORMl3MTY5pcWKrdIOgZ4VtdCCpcn;3eIg>NFi1S5UyOjZ|MU[xPS=>
U266/LR7Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zPflUxOCCwZz;tcC=>M{D6ZVQ5KGh?NHvLbnRFVVORMXPJcohq[mm2czDj[YxtKGe{b4f0bC=>MXexNlY{OTZzOR?=
U266/dox4MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPnOVAxKG6pL33sNYXZUXpRPDhiaB?=NVS0NY03TE2VTx?=M3HRVWlvcGmkaYTzJINmdGxiZ4Lve5RpMlTZNVI3OzF4MUm=
RPMI8226/LR5NWDCSpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHFOVAxKG6pL33sMnW0OFghcA>?NIjlN5FFVVORMYDJcohq[mm2czDj[YxtKGe{b4f0bC=>MUWxNlY{OTZzOR?=
H460M{fCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVmxNEDPxE1?NF;jd3E4OiCqMYnEUXNQNF[zSpNKSzVyPUGwNEBvVQ>?NEHVR4IyOjZ|MU[yNC=>
H358NWXOdZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUSxNEDPxE1?MlWwO|IhcA>?M1vYN2ROW09?NVS0WFNVUUN3ME23NEBvVQ>?MnTzNVI3OzF4MkC=
H322MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU[xNEDPxE1?NWnM[ZJrPzJiaB?=MVPEUXNQNH3NN4tKSzVyPU[yNEBvVQ>?NYL4W4xHOTJ4M{G2NlA>
H460M2\HWmZ2dmO2aX;uJGF{e2G7MUexNFAhdk1?NELaUGozPCCqMUnEUXNQMmXJTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>?MUGxNlY{OTZ{MB?=
LNCap-Pro5M1PWNGZ2dmO2aX;uJGF{e2G7NIK1VFQyKM7:TR?=MlriOEBpMX\EUXNQM{TtXXN1[WKrbHn6[ZMheDV|NH[yfWgyPDZzMkWzNi=>
T29NFLtTHRCeG:ydH;zbZMhSXO|YYm=MXe1NEBvVQ>?NWDOU4VvPDhiaDC=NXfWSJk6TE2VTx?=MWLJcoR2[2W|IHPlcIwh[XCxcITvd4l{NXO1cIw1OTZ5N{ixO|k>
T29Kt1NFvkNHhCeG:ydH;zbZMhSXO|YYm=MmHNOVAhdk1?MUC0PEBpKA>?MnrCSG1UVw>?MniyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?Ml6xNVY4PzhzN{m=
HCT116MlnJRZBweHSxc3nzJGF{e2G7MljPOVAhdk1?NVTPXI1PPDhiaDC=M{[xeGROW09?NYTKPI5LUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=M{XmR|E3Pzd6MUe5
HKe-3NFzJV5FCeG:ydH;zbZMhSXO|YYm=NGLabIU2OCCwTR?=MknnOFghcCB?MY\EUXNQNWDSRnN6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=MV6xOlc4QDF5OR?=
NB-1691NY\v[4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUWxJO69VQ>?NUjKepdiPzJiaB?=M2TxRmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?=MV6xO|Y5QTZ6NB?=
CHLA-255MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zBUFEh|ryPMlnsO|IhcA>?NVTxe2RUUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKlM3OyeVE4Pjh7Nki0
SK-N-ASMmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmSwNUDPxE1?NH;udII4OiCqNUm1Wo1HUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=>NXHLNIhVOTd4OEm2PFQ>
NB-1691NF\NRXFHfW6ldHnvckBCe3OjeR?=MXyxNEBvVQ>?MkjpNlQhcA>?M3[4XHNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U>MYWxO|Y5QTZ6NB?=
CHLA-255MoTRSpVv[3Srb36gRZN{[Xl?NFr6RpMyOCCwTR?=MkHaNlQhcA>?MVjNc4Rme3SueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>?NEWyU3kyPzZ6OU[4OC=>
RPMI 8226Mm[4SpVv[3Srb36gRZN{[Xl?MkjoNlAhdk1?NVvNR2FIQCCqM{LPVHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6MmPsNVk1OzZyNUC=
MM.1SNXnzVVR1TnWwY4Tpc44hSXO|YYm=M4Tl[VIxKG6PMWi4JIg>NYTn[nNnW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?MoXLNVk1OzZyNUC=
U266NHnp[G5HfW6ldHnvckBCe3OjeR?=NHmySWkzOCCwTR?=MlzyPEBpMoDKV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk>MUSxPVQ{PjB3MB?=
OPM1MlfySpVv[3Srb36gRZN{[Xl?MYeyNEBvVQ>?NEPicWM5KGh?M1P0OXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6M4HUcFE6PDN4MEWw
INA6NY\WTmJnTnWwY4Tpc44hSXO|YYm=NVv5eYg2OjBibl2=NIOxeXY5KGh?NWPRZ2EzW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?NYXQe3o5OTl2M{[wOVA>
OPM2M3zjWmZ2dmO2aX;uJGF{e2G7MVeyNEBvVQ>?M2\uNVghcA>?NFzLRZdUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>?NHz5cVkyQTR|NkC1NC=>
RPMI 8226MkLwSpVv[3Srb36gRZN{[Xl?M3zsdFIxKG6PMY[4JIg>NGjVNWNKdmS3Y3XzJGRPSSC|eX70bIV{cXN?Mn3kNVk1OzZyNUC=
BaF/3MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXmxNFAhdk1?NIPIR4M1QCCqMWTJR|UxRTZwMjDuUS=>NFvKUXIzODNyNU[5Ni=>
BaF/3-p210NGOycGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjkUmIyODBibl2=NIjJenY1QCCqNEDSXpdKSzVyPUSuO{BvVQ>?M2PwRlIxOzB3Nkmy
TCC-SMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVftOHVlOTByIH7NM4f5XlQ5KGh?M2HvTGlEPTB;Mj64JI5OMn;QNlA{ODV4OUK=
BaF/3MlXaSpVv[3Srb36gRZN{[Xl?MkDLOkBvVQ>?MUi0PEBpMkPiTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0NXjpVpAzOjB|MEW2PVI>
BaF/3-p210NX\JWo9bTnWwY4Tpc44hSXO|YYm=Mli0OkBvVQ>?NFq1TVE1QCCqMV\JcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0MUKyNFMxPTZ7Mh?=
BaF/3-p210NIrWV|JHfW6ldHnvckBCe3OjeR?=NX;yR4l5PiCwTR?=MlXnNlQhcA>?MmfjVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ?NYfYc4pNOjB|MEW2PVI>
RajiNXTt[oZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXSxJO69VQ>?NUjBdYpEOjRiaB?=M4fGdXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=M4HYWlIyOTdyOUi4
LCL-1NVHJcVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\ITHZ1OSEQvF2=NVzHeHlCOjRiaB?=NUjoWI4{WmWmdXPld{Bk\WyuII\pZYJqdGm2edMgMUCyNVE4ODl6OB?=
LCL-2M{fJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoOwNUDPxE1?Ml\zNlQhcA>?NF7He3pT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=NGn6PGIzOTF5MEm4PC=>
BJABNUTBXohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDufJYyKM7:TR?=MWqyOEBpM4\EdXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NETkXmMzOTF5MEm4PC=>
SNT-13MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLLfnVbOSEQvF2=Mn;PNlQhcA>?M2PPc3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NWjUe5RxOjFzN{C5PFg>
SNT-16Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{i5RVEh|ryPMWCyOEBpNEPHeZdT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=NG\IZo4zOTF5MEm4PC=>
JurkatMkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{n2ZVEh|ryPM3fWWFI1KGh?MoKxVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiMk\lNlEyPzB7OEi=
KAI-3M1yyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfHW2g6OSEQvF2=NXXWSIxPOjRiaB?=M365U3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=MUeyNVE4ODl6OB?=
SNK-6M{TYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXf1[4twOSEQvF2=MVKyOEBpM4XWW3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NIm4TlYzOTF5MEm4PC=>
KHYG-1M1K2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfGOY8yKM7:TR?=NUPENJdjOjRiaB?=NIDqN2RT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MW[yNVE4ODl6OB?=
SNT-16M3rze2Fxd3C2b4Ppd{BCe3OjeR?=Mn7HNUDPxE1?M2K0S|YhcA>?MX;JcoR2[2W|IHPlcIwh[XCxcITvd4l{MU[yNVE4ODl6OB?=
JurkatMlvoRZBweHSxc3nzJGF{e2G7NXTnZZc2OSEQvF2=NGflOI83KGh?M4r5Umlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?MUCyNVE4ODl6OB?=
KAI-3MnWxRZBweHSxc3nzJGF{e2G7Mlr3NUDPxE1?NWXTRm43PiCqNXvwWVNDUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=MmPONlEyPzB7OEi=
KHYG-1MX3BdI9xfG:|aYOgRZN{[Xl?Mn7INUDPxE1?NVjmWlduPiCqM{ns[2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN?M{jlXVIyOTdyOUi4
SNT-13NV;zNoh{SW62aY\pdoFtKEG|c3H5M4C1clEh|ryPM4nLfFI1KGh?Mo[0TY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJXMlr5NlEyPzB7OEi=
SNT-16MY\BcpRqfmm{YXygRZN{[Xl?MkLZNUDPxE1?NGfiVZQzPCCqNHLDbIhKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?MYSyNVE4ODl6OB?=
KAI-3M{mzfGFvfGm4aYLhcEBCe3OjeR?=M2HRS|Eh|ryPM3fPT|I1KGh?NFHhcGFKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?MVOyNVE4ODl6OB?=
SNK-6NVHvcWI3SW62aY\pdoFtKEG|c3H5MVOxJO69VQ>?MX2yOEBpNV;vR445UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKYMUOyNVE4ODl6OB?=
RAW 264.7MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH5bI9ZOTByIH7NMoDoOFghcA>?NXfQNZBOWmWmdXPld{Bk\WyuII\pZYJqdGm2edMgNHHDdVczOjR{N{G1OC=>
A375MlnzRZBweHSxc3nzJGF{e2G7NITiUXgyOCCwTR?=MWeyOEBpM3r6WGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?M1rGW|I{ODd7MEiz
BLMNWfIVVFLSXCxcITvd4l{KEG|c3H5M1HWcVExKG6PMm\UNlQhcA>?NX76XVFQUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=NG\Id2czOzB5OUC4Ny=>
A375M3nYTGF2fG:yaHHnfUBCe3OjeR?=Ml\LNVAhdk1?M1S0OFEzKGh?NVv6bppZUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>M1;EbFI{ODd7MEiz
BLMNXX4fGN5SXW2b4DoZYd6KEG|c3H5NFLsOpEyOCCwTR?=Mmn6NVIhcA>?NGLDRmxKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=>MWWyN|A4QTB6Mx?=
H1299NIrpfXNCeG:ydH;zbZMhSXO|YYm=NXzF[4RvQDBibl2=Mn\3NlQhcA>?NEnRPWxFVVORNUXXZoJZW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO=M1fKcFI2OzJ|Nkmz
Hut-78MnzRSpVv[3Srb36gRZN{[Xl?NH;kSIwyODBibl2=M3vaXFI1KGh?NVfWN5Y{TE2VTx?=MXXEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVExKGW6cILld5Nqd25?M1fDOlI2PjhzM{O1
H9M1jlR2Z2dmO2aX;uJGF{e2G7NGTjRYsyODBibl2=NX\leG1[OjRiaB?=MYHEUXNQNHHUNpZFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36=M3zvfFI2PjhzM{O1
HHMlnnSpVv[3Srb36gRZN{[Xl?MnP4NVAxKG6PNXHnN|VLOjRiaB?=MoHxSG1UVw>?NHm5UYZld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36=NIDrdpMzPTZ6MUOzOS=>
Hut-78NVLycVRYVWmpcnH0bY9vKEG|c3H5MoTZNVAxKG6PMl3INlQhcA>?MlzXSG1UVw>?MmHpVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?=MoXGNlU3QDF|M{W=
HHM2PFUm1q\3KjdHnvckBCe3OjeR?=NFfqdHIyODBibl2=MWKyOEBpMVnEUXNQNYD6cYhrWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=>MlLHNlU3QDF|M{W=
U937MU\GeY5kfGmxbjDBd5NigQ>?NWDMWGc6OTByIH7NMl;0OkBpM3fxVGlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN?NGH1SXAzPTd7MUS3Oy=>
human PBMCMnnGSpVv[3Srb36gRZN{[Xl?NF3RdIYyODBibl2=M17qUlI1KGh?MnT0TY5lfWOnczDJUE05KHKnbHXhd4U>MUiyOVc6OTR5Nx?=
ES6NELob5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDVTWM2OD1yLkCwNlEhdk1?NEfvfFVUSU6JRWK=
SK-UT-1M2DLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjZSotSUUN3ME2wMlE3OyCwTR?=NUD0[opMW0GQR1XS
SH-4NIrSNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTBwMUezJI5OM3;iUXNCVkeHUh?=
TE-9NGLyfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTBwMUiyJI5OMl3rV2FPT0WU
A253M2fQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jpS2lEPTB;MD6yNFghdk1?MY\TRW5ITVJ?
no-10M{P3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHoclhKSzVyPUCuNlEhdk1?NEDYNmFUSU6JRWK=
MMAC-SFNF73N3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LEcGlEPTB;MD6yNVYhdk1?M4\PXXNCVkeHUh?=
A101DMn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rZfGlEPTB;MD6yNlUhdk1?NXrkXW1QW0GQR1XS
NTERA-S-cl-D1M{P4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHTTWM2OD1yLkK0N{BvVQ>?NFvoUVFUSU6JRWK=
8-MG-BANG\uSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7NTWM2OD1yLkK1JI5OMVHTRW5ITVJ?
KNS-42MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMkW4JI5ONH:wXnRUSU6JRWK=
LXF-289MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HLO2lEPTB;MD6yOlkhdk1?NFjQPFFUSU6JRWK=
OVCAR-4M1G0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\CdWJPUUN3ME2wMlI5QSCwTR?=NHH2NmtUSU6JRWK=
LOUCYMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTBwMkmzJI5OMXPTRW5ITVJ?
BB65-RCCMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TMdGlEPTB;MD6zNFQhdk1?MVvTRW5ITVJ?
D-542MGMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwM{K5JI5OMVHTRW5ITVJ?
ONS-76MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3r1TGlEPTB;MD6zN{BvVQ>?NFXNWY5USU6JRWK=
BB30-HNCNH7rb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3mS3lvUUN3ME2wMlM{PSCwTR?=M{\YVXNCVkeHUh?=
KS-1NGLXSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfoTWM2OD1yLkO0JI5OMlvFV2FPT0WU
A388M4jZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwM{W2JI5OMofJV2FPT0WU
ES8M2L4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHBcopKSzVyPUCuOEBvVQ>?NF3rNllUSU6JRWK=
MZ2-MELMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnr6TWM2OD1yLkSwO{BvVQ>?NYToe5N[W0GQR1XS
HCC2998MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\VTWM2OD1yLkSxNkBvVQ>?MVnTRW5ITVJ?
D-247MGMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTBwNEGzJI5OMn70V2FPT0WU
ACNMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTBwNEG3JI5OM{j1WHNCVkeHUh?=
LB2518-MELMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\mZmtuUUN3ME2wMlQzPSCwTR?=NYXRbllqW0GQR1XS
ES1NV2wc5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPlTWM2OD1yLkSzJI5OMUXTRW5ITVJ?
HCE-TNXPLPHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDrTWM2OD1yLkSzPUBvVQ>?NIDqNo9USU6JRWK=
OS-RC-2NFnvTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\pVYpKSzVyPUCuOFQhdk1?MVHTRW5ITVJ?
MFH-inoNHq5eoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLCe2Z6UUN3ME2wMlQ1OyCwTR?=NIXtbZNUSU6JRWK=
OCUB-MNHyze4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXniOHJJUUN3ME2wMlQ1PyCwTR?=NXXSR5pCW0GQR1XS
CP66-MELM3\Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnhWGs5UUN3ME2wMlQ4OyCwTR?=MWTTRW5ITVJ?
LB771-HNCNEH1e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDTS5ZKSzVyPUCuOFc1KG6PMW\TRW5ITVJ?
DSH1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XBXWlEPTB;MD60PEBvVQ>?M2\r[3NCVkeHUh?=
HUTU-80M3XHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjSTWM2OD1yLkWzN{BvVQ>?NXnueYpjW0GQR1XS
CESSNYDhVY5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mke0TWM2OD1yLkWzPEBvVQ>?NI\SO4JUSU6JRWK=
NCI-H747NYXpSlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjrcotKSzVyPUCuOVM6KG6PNGPlW3VUSU6JRWK=
HT-144NVLsUINGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;6TWM2OD1yLkW3OkBvVQ>?NFLPSoRUSU6JRWK=
COLO-829MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn0ZXFKSzVyPUCuOlE1KG6PNIHY[mtUSU6JRWK=
A4-FukM{fSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwNkKzJI5ONU[2VGl2W0GQR1XS
GI-ME-NNG\VT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnuwTWM2OD1yLk[zOEBvVQ>?MVvTRW5ITVJ?
LB831-BLCNYfTRZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLRTWM2OD1yLk[0NUBvVQ>?M3O2THNCVkeHUh?=
HOP-62NEnqWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFryWXRKSzVyPUCuOlQ4KG6PNHLSXWtUSU6JRWK=
BB49-HNCNFq2eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml6zTWM2OD1yLk[1NkBvVQ>?MUTTRW5ITVJ?
D-336MGNYfIV4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn:2TWM2OD1yLk[1O{BvVQ>?M3;iTXNCVkeHUh?=
TK10NYW1fJNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXoWZUxUUN3ME2wMlY4QSCwTR?=M{DzSHNCVkeHUh?=
Ramos-2G6-4C10M3m5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHGZXliUUN3ME2wMlY6OyCwTR?=Mo\PV2FPT0WU
LB373-MEL-DMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLJPGRUUUN3ME2wMlchdk1?NXGyOZoxW0GQR1XS
SF126NG\3[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzLTWM2OD1yLkewNUBvVQ>?M4[y[HNCVkeHUh?=
UACC-257MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwN{Ggcm0>M{TzbnNCVkeHUh?=
KINGS-1NWnCdnQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVy3WmFvUUN3ME2wMlczOiCwTR?=NVPUUHF1W0GQR1XS
LS-513MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PR[GlEPTB;MD63N|khdk1?NGDuO5FUSU6JRWK=
GI-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGC2fFFKSzVyPUCuO|Y1KG6PM{nzUnNCVkeHUh?=
ES7MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\VTWM2OD1yLke2OkBvVQ>?NVrESYxFW0GQR1XS
LB2241-RCCM{XOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fVN2lEPTB;MD64NFQhdk1?NYDUeJZVW0GQR1XS
D-263MGM1Xh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTBwOEC3JI5OM3vXbXNCVkeHUh?=
SW684MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j0bGlEPTB;MD64NlEhdk1?MUTTRW5ITVJ?
ML-2MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fXWGlEPTB;MD64NlEhdk1?Mn;xV2FPT0WU
SK-LMS-1NYX5XnU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\vcpVXUUN3ME2wMlg2PCCwTR?=NHnTeldUSU6JRWK=
TE-5MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfXTWM2OD1yLki2OUBvVQ>?NYDOeXlzW0GQR1XS
QIMR-WILNEDEOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrCPZdqUUN3ME2wMlg5QSCwTR?=NYC4cplVW0GQR1XS
NCI-H1355M2m4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwOEm1JI5OMWTTRW5ITVJ?
SNB75MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvYTWM2OD1yLkmxNkBvVQ>?MYLTRW5ITVJ?
RXF393NYnVVo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwOUG0JI5OMnHJV2FPT0WU
IST-MEL1NYDvbWNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPhTWM2OD1yLkmxO{BvVQ>?NF7CbY1USU6JRWK=
SF268NIDS[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwOUKzJI5OMYjTRW5ITVJ?
KALS-1NXnJVlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1e3PWlEPTB;MD65NlUhdk1?NUXGfJVbW0GQR1XS
HC-1NHL0Vo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvuTWM2OD1yLkm3OUBvVQ>?MUfTRW5ITVJ?
SW872NYfL[m9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGyO|RKSzVyPUCuPVk3KG6PNVrUfXgyW0GQR1XS
PSN1Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\TTWM2OD1zLkCxJI5OMYrTRW5ITVJ?
TE-1Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTFwMEOgcm0>M1ntXHNCVkeHUh?=
TE-10MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPJTFM3UUN3ME2xMlA{KG6PNUDj[pR4W0GQR1XS
RKOM2rZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTFwME[gcm0>NGHVcIRUSU6JRWK=
LC-2-adNFP4XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPrb2dKSzVyPUGuNFghdk1?MUXTRW5ITVJ?
SK-MM-2NULjUmZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDHTWM2OD1zLkC5JI5OMV3TRW5ITVJ?
VA-ES-BJNVfTZ|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4C1bWlEPTB;MT6wPUBvVQ>?NUHocYxqW0GQR1XS
MZ7-melMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjPTWM2OD1zLkC5JI5OMmq0V2FPT0WU
D-392MGM3ftO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;rdHo2UUN3ME2xMlEhdk1?MVLTRW5ITVJ?
CCRF-CEMMlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXHTWM2OD1zLkGzJI5OMVvTRW5ITVJ?
EM-2MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTFwMU[gcm0>NULYOnRSW0GQR1XS
HAL-01M4\E[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHiWZY2UUN3ME2xMlE5KG6PNGXSZpZUSU6JRWK=
TE-8NGnifHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFwMUmgcm0>MVnTRW5ITVJ?
NCI-H1882NHXJc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG5cpg2UUN3ME2xMlIhdk1?MUDTRW5ITVJ?
DaudiNYXPfllxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfTNWNvUUN3ME2xMlIzKG6PNGHRb5BUSU6JRWK=
BL-41NFX2fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrxTWM2OD1zLkK1JI5OMlu4V2FPT0WU
SRMoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqwZW45UUN3ME2xMlI2KG6PMVHTRW5ITVJ?
KM12NGDrWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTFwMkegcm0>MkG4V2FPT0WU
K5NXzUdY1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrKbHZKSzVyPUGuNlghdk1?NXywdlF1W0GQR1XS
A3-KAWNW[3OJZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGe2S5hKSzVyPUGuNlghdk1?M2WzSnNCVkeHUh?=
CMKMlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1mxcWlEPTB;MT6yPUBvVQ>?NUThRYFiW0GQR1XS
Calu-6NH3zZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzNbmNKSzVyPUGuNlkhdk1?M1PlUHNCVkeHUh?=
IST-SL2M3;GfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXsTWM2OD1zLkOxJI5ONWHWfJVvW0GQR1XS
OPM-2M{LkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFwM{Ogcm0>NFm0XZpUSU6JRWK=
DU-4475M3u3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFwM{[gcm0>NWfi[WdmW0GQR1XS
ECC12MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETWVndKSzVyPUGuN|chdk1?MWTTRW5ITVJ?
L-540MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmr2TWM2OD1zLkO3JI5OMlP0V2FPT0WU
CAS-1M13LUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGiyVJNKSzVyPUGuN|chdk1?MVnTRW5ITVJ?
PF-382MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nueWlEPTB;MT60O{BvVQ>?MXfTRW5ITVJ?
LS-411NNX60fHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3r0WWlEPTB;MT61N{BvVQ>?MUfTRW5ITVJ?
NCI-H69NF;hWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnNTWM2OD1zLkW0JI5OM{SxeXNCVkeHUh?=
NB12M{TM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTFwNU[gcm0>MWHTRW5ITVJ?
HELMknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoX6TWM2OD1zLk[xJI5OMlzkV2FPT0WU
GCIYM2PUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTFwNkKgcm0>NWi1fpZFW0GQR1XS
EHEBM3zlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Hp[GlEPTB;MT62O{BvVQ>?MkPQV2FPT0WU
TGBC1TKBM{CxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;3OVNKUUN3ME2xMlcyKG6PNFn0R|FUSU6JRWK=
KURAMOCHIMmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLiTWM2OD1zLkeyJI5OMX;TRW5ITVJ?
U-266NILsSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXqTWM2OD1zLke2JI5ONYD5UVlGW0GQR1XS
LC4-1M1rITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELhU4hKSzVyPUGuO|khdk1?MlizV2FPT0WU
NCI-H2126M3vFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnmxTWM2OD1zLkigcm0>M1[2SXNCVkeHUh?=
NCI-H1092M{fKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33R[WlEPTB;MT64JI5ONIfXbZZUSU6JRWK=
GB-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jmUmlEPTB;MT64NUBvVQ>?MmPZV2FPT0WU
MV-4-11M1myXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTFwOEKgcm0>NVuzcmd7W0GQR1XS
BeckerM37YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLNSY9KSzVyPUGuPFMhdk1?NXjUfZdyW0GQR1XS
MPP-89Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M161d2lEPTB;MT64PUBvVQ>?M1PNTnNCVkeHUh?=
BE-13NYfOVmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwOUOgcm0>NFL4[JRUSU6JRWK=
697NV:xc5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTSTWM2OD1zLkm5JI5OMkHzV2FPT0WU
NKM-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJibl2=MoXPV2FPT0WU
NB13NETQfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTJibl2=NYXU[49jW0GQR1XS
LS-123M{S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PhO2lEPTB;Mj6wNkBvVQ>?NXfTc|ZtW0GQR1XS
NB17M3;Bdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmP2TWM2OD1{LkC0JI5ONF[x[5VUSU6JRWK=
LAN-6NW[w[Go4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13v[WlEPTB;Mj6wOUBvVQ>?MUXTRW5ITVJ?
EW-24MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DZWmlEPTB;Mj6wPEBvVQ>?MW\TRW5ITVJ?
NOS-1MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLjTWM2OD1{LkGxJI5OM{DLdnNCVkeHUh?=
BL-70NGjpWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLVTWM2OD1{LkGyJI5OM2XnR3NCVkeHUh?=
GT3TKBNWjKZmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorFTWM2OD1{LkGyJI5ONXjmUZp7W0GQR1XS
HHNWHpfIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvBTWM2OD1{LkGzJI5OMoHMV2FPT0WU
KE-37MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJwMUOgcm0>NYnw[WRSW0GQR1XS
MOLT-4MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jBZmlEPTB;Mj6xN{BvVQ>?NYP6VYIyW0GQR1XS
EKVXM3G4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDBb2FKSzVyPUKuNVQhdk1?NW\RSmlUW0GQR1XS
KGNMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTETWM2OD1{LkG1JI5ONF25V4lUSU6JRWK=
ES4NFnmZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTJwMU[gcm0>MXzTRW5ITVJ?
SJSA-1NF3jTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zSWmlEPTB;Mj6yNUBvVQ>?MnPnV2FPT0WU
KMOE-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJwMkOgcm0>MVrTRW5ITVJ?
NB5MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGD5UlZKSzVyPUKuNlchdk1?MXTTRW5ITVJ?
BC-1NI\vcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4e0R2lEPTB;Mj6zNUBvVQ>?MkPBV2FPT0WU
NB10M1uxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jIPGlEPTB;Mj6zNkBvVQ>?M3\ac3NCVkeHUh?=
RPMI-8226NILrNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLQTWM2OD1{LkO1JI5ONIO5ZXlUSU6JRWK=
SCC-3NYPEVW9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HwO2lEPTB;Mj6zO{BvVQ>?MmPmV2FPT0WU
ARH-77NWD0UndQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fzOGlEPTB;Mj6zPEBvVQ>?MVHTRW5ITVJ?
NCI-H748M2PyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVr3cG9tUUN3ME2yMlM6KG6PMnnTV2FPT0WU
KU812NX7ac|BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnDV|VKSzVyPUKuOFIhdk1?NH3jWINUSU6JRWK=
NCI-H64MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DzPGlEPTB;Mj60OEBvVQ>?MmT2V2FPT0WU
NB69NFG3RVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfvTWM2OD1{LkS2JI5ONXXmdnJlW0GQR1XS
KNS-81-FDMl3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\RSFQ2UUN3ME2yMlQ5KG6PNFz4TGFUSU6JRWK=
LB1047-RCCMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTYd4lKSzVyPUKuOVchdk1?NGr2O|RUSU6JRWK=
EB-3NY\md3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e2e2lEPTB;Mj62OkBvVQ>?MmnGV2FPT0WU
Mo-TM1mxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUn5T4lHUUN3ME2yMlc1KG6PNX;5TnFlW0GQR1XS
EW-16MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXP0XnU5UUN3ME2yMlc2KG6PMXrTRW5ITVJ?
CTV-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TrcmlEPTB;Mj64JI5ONEXQSZBUSU6JRWK=
ETK-1NV;4SGJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fmZWlEPTB;Mj64OEBvVQ>?NFvPS45USU6JRWK=
C2BBe1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFG0TWFKSzVyPUKuPFkhdk1?NYTPSGJPW0GQR1XS
MOLT-16NH\GR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TJcmlEPTB;Mj64PUBvVQ>?MnvjV2FPT0WU
SW954NUHGWpZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLsSIdKSzVyPUKuPUBvVQ>?M4nCVXNCVkeHUh?=
HTMmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTNwMEKgcm0>NFf0Rm9USU6JRWK=
KARPAS-299MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTNwME[gcm0>MVPTRW5ITVJ?
MONO-MAC-6NYLZNmVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTNwMTDuUS=>NFPOSZBUSU6JRWK=
CGTH-W-1NY\ZTW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\VU2ZKSzVyPUOuNUBvVQ>?NHXaVJNUSU6JRWK=
SK-PN-DWMn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jEeWlEPTB;Mz6xOEBvVQ>?MmrHV2FPT0WU
CW-2MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrLclhKSzVyPUOuNlEhdk1?NEX0bG1USU6JRWK=
SK-N-DZMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTnWpA1UUN3ME2zMlI3KG6PMYjTRW5ITVJ?
NEC8M4\ZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zlb2lEPTB;Mz6zOUBvVQ>?NHHGc5NUSU6JRWK=
LB996-RCCNH\TS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIH6U4RKSzVyPUOuOEBvVQ>?NX:0R4V4W0GQR1XS
DBMn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPtZ2NKSzVyPUOuOFEhdk1?NUjTW|VRW0GQR1XS
TE-15M4XZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFj1UWlKSzVyPUOuOFMhdk1?NXXYZVlpW0GQR1XS
COR-L88Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL3eoR7UUN3ME2zMlQ4KG6PM1;YZXNCVkeHUh?=
LAMA-84M3ixbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL3OldCUUN3ME2zMlQ6KG6PMWPTRW5ITVJ?
MEG-01NXHBfYxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTNwNEmgcm0>NFm1OG9USU6JRWK=
LOXIMVINYr4dY95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHWW|ZKSzVyPUOuOUBvVQ>?NEnNcWZUSU6JRWK=
RPMI-8402NXLzeJdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTNwNTDuUS=>M2GzU3NCVkeHUh?=
KARPAS-45MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnWfWt6UUN3ME2zMlU1KG6PNX;nVHIxW0GQR1XS
HCC1187MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrUVYIyUUN3ME2zMlU1KG6PMVTTRW5ITVJ?
MZ1-PCM1;LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLyNGtKSzVyPUOuOVQhdk1?MUfTRW5ITVJ?
no-11NFfETWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTNwNUWgcm0>MX3TRW5ITVJ?
EVSA-TM17nOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrtTWM2OD1|Lk[gcm0>NULpWnQ2W0GQR1XS
DJM-1NVT6XVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfofpRvUUN3ME2zMlY{KG6PMmHKV2FPT0WU
COLO-684NYnreYZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTNwNk[gcm0>NYX6VoU{W0GQR1XS
NMC-G1M3O1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTNwNkigcm0>M2XGcHNCVkeHUh?=
LC-1FNUjPb4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFS3TFRKSzVyPUOuO|Qhdk1?MmSwV2FPT0WU
RL95-2MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTNwN{mgcm0>NXe4fJg{W0GQR1XS
COLO-320-HSRNEjCU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4C5TWlEPTB;Mz65NkBvVQ>?MYfTRW5ITVJ?
RCC10RGBNXTJWGZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEi0coFKSzVyPUOuPVMhdk1?NW\FUmRqW0GQR1XS
HD-MY-ZM13zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljXTWM2OD1|LkmzJI5OM3PPV3NCVkeHUh?=
NCI-H2141NImycopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXP4OXJ3UUN3ME20MlA2KG6PMWHTRW5ITVJ?
K-562MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTRwMUKgcm0>M33h[3NCVkeHUh?=
NCI-H1648MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzheWV2UUN3ME20MlE{KG6PNIHHT|JUSU6JRWK=
OMC-1NGnYbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37Z[mlEPTB;ND6xPEBvVQ>?MkfjV2FPT0WU
LB647-SCLCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;0O2lEPTB;ND6yNkBvVQ>?MmPBV2FPT0WU
TE-12NInUe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTRwMkWgcm0>Mo\LV2FPT0WU
NOMO-1M1u5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XWdmlEPTB;ND6zN{BvVQ>?NF\ucZlUSU6JRWK=
RajiM{S4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4ft[2lEPTB;ND60OkBvVQ>?MXXTRW5ITVJ?
NALM-6M{K1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofoTWM2OD12LkS5JI5ONWfOdXNTW0GQR1XS
HL-60NV22bnhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\yVnV3UUN3ME20MlY4KG6PM3m0dXNCVkeHUh?=
IST-SL1M{XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PyRmlEPTB;ND62PEBvVQ>?MoKwV2FPT0WU
MHH-PREB-1Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LEWWlEPTB;ND64OkBvVQ>?M{XsbHNCVkeHUh?=
MHH-NB-11NGXIS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTRwOUGgcm0>M4DyT3NCVkeHUh?=
JiyoyeP-2003NEf1Z4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYCx[4tvUUN3ME21JI5OMlriV2FPT0WU
SBC-1M{fnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTVTWM2OD13LkCxJI5OM4XFWXNCVkeHUh?=
CHP-126Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnOendoUUN3ME21MlA3KG6PM{\JPHNCVkeHUh?=
LU-139MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV6wWJI1UUN3ME21MlE{KG6PMYrTRW5ITVJ?
NCI-SNU-5MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3VTWM2OD13LkG3JI5OM3XiN3NCVkeHUh?=
SW962NX;nTodpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1W2R2lEPTB;NT6yNUBvVQ>?NGm1O2dUSU6JRWK=
EW-1M{TIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;2TWM2OD13LkOxJI5ONHPk[IJUSU6JRWK=
NCI-H1417M4DZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTVwNUGgcm0>NYexWWgzW0GQR1XS
LU-65MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjCRYlsUUN3ME21Mlg1KG6PNXXxNXM1W0GQR1XS
D-502MGMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TU[GlEPTB;Nj6zO{BvVQ>?MlTLV2FPT0WU
BC-3NGLM[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTZwNkGgcm0>MXHTRW5ITVJ?
GDM-1M1znU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnUfHZpUUN3ME22Mlc4KG6PNV7OTo46W0GQR1XS
NCI-H2196NXnVO|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnYc4JUUUN3ME22Mlghdk1?NHnkOGJUSU6JRWK=
NB1M4K2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Tzd2lEPTB;Nj64PEBvVQ>?NGmze3pUSU6JRWK=
NCI-H345MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfxO5ZZUUN3ME23MlIhdk1?NGKx[FZUSU6JRWK=
SU-DHL-1NWW4[5ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTdwMkSgcm0>MmfxV2FPT0WU
JVM-2NGX5[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;COXpKSzVyPUeuNlghdk1?MVTTRW5ITVJ?
LU-134-ANV72ZnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfUXXBKSzVyPUeuN|khdk1?M3TsWXNCVkeHUh?=
NCI-H1694NWPZRotrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XHc2lEPTB;Nz61PEBvVQ>?MlPOV2FPT0WU
NCI-SNU-16M1jWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTKTWM2OD15Lk[1JI5OMnnMV2FPT0WU
L-363MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTdwNzDuUS=>NGXTeoZUSU6JRWK=
KG-1NXS3XIFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXLWYdKSzVyPUeuPVQhdk1?M33mPXNCVkeHUh?=
MN-60NETTOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHBZnNKSzVyPUiuNVQhdk1?MUDTRW5ITVJ?
NB6NVLGdlhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrNS5pKSzVyPUiuOFghdk1?NHHhZnlUSU6JRWK=
MLMAM1qzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nsTWlEPTB;OD64OUBvVQ>?MV\TRW5ITVJ?
ATN-1MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELFfnJKSzVyPUiuPFkhdk1?NYTYbYpYW0GQR1XS
SK-NEP-1M1\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXuWlVKSzVyPUmuNFEhdk1?NWf1e5VFW0GQR1XS
DMS-114M{nYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLUTWM2OD17Lk[yJI5OMYPTRW5ITVJ?
CTB-1NXXwV3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2T6cWlEPTB;OT62O{BvVQ>?NYjDOnR7W0GQR1XS
NCI-H2081NIriT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:2TVNKSzVyPUGwMlA6KG6PNEPCdXJUSU6JRWK=
ES5M1m1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7FdVBrUUN3ME2xNE4{QCCwTR?=NVHteYJCW0GQR1XS
HCC1599MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPMNFdKSzVyPUGxMlkyKG6PMlu2V2FPT0WU
NCI-H23MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF{LkGyJI5ONXzzSFlxW0GQR1XS
NCI-H1581M3:3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3ITWM2OD1zMj6yPEBvVQ>?NVzDNndDW0GQR1XS
JVM-3NWXlXoRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrOTWM2OD1zMj65PUBvVQ>?NYfjUoVNW0GQR1XS
NCI-SNU-1MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjuZ5FKSzVyPUGzMlE6KG6PMlq2V2FPT0WU
NB7NXLmbng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[1emRKSzVyPUG1MlkzKG6PNH;xdGlUSU6JRWK=
JARNHXWTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn6U4VKSzVyPUG2MlE{KG6PMmXLV2FPT0WU
TGWMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvGTWM2OD1zNj60PEBvVQ>?NVvQNHFIW0GQR1XS
U-87-MGNVjae3FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\udYdKSzVyPUG2Mlc3KG6PMmfzV2FPT0WU
NCI-H1436MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3tZpUyUUN3ME2xO{4xOSCwTR?=MljxV2FPT0WU
GOTONWO3V4QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1[0dWlEPTB;MUeuNFYhdk1?NFr5eFRUSU6JRWK=
COLO-800M3nyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPWSmFKSzVyPUG3MlY1KG6PM2e2dnNCVkeHUh?=
MFM-223M{G0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF5LkmxJI5OMYXTRW5ITVJ?
EW-18MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTF5Lkm2JI5ONUjoNWpQW0GQR1XS
NB14NGfwO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGf1bJJKSzVyPUG3Mlk5KG6PMnz5V2FPT0WU
EB2Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHRO4VTUUN3ME2xPE4xQCCwTR?=MUXTRW5ITVJ?
EoL-1-NFzkfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\ZNYRFUUN3ME2xPE4{OSCwTR?=Mn7EV2FPT0WU
NCCITNITGN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTF6LkO2JI5OM3HYcXNCVkeHUh?=
DG-75M{H5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1u2OWlEPTB;MUiuOlEhdk1?MYDTRW5ITVJ?
HCC2218NWL0SXluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELrZXNKSzVyPUG5MlUhdk1?MnH6V2FPT0WU
TE-6M1Tzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjKTWM2OD1{MD6wPEBvVQ>?MY\TRW5ITVJ?
SF539M37Hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTwUYNQUUN3ME2yNE43PyCwTR?=MVPTRW5ITVJ?
NCI-H446NVe5VmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX1R3dKSzVyPUKxMlE5KG6PNUPURlZ6W0GQR1XS
IST-MES1M2LYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPjSJJ2UUN3ME2yNk44PyCwTR?=NF3odJRUSU6JRWK=
NCI-H82MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTJ|LkCyJI5ONWTwfI1TW0GQR1XS
HCC2157NGHmT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHv4V4JKSzVyPUKzMlE{KG6PNVXkUJozW0GQR1XS
EW-12NVTKSXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n0WmlEPTB;MkOuNVchdk1?M3H1c3NCVkeHUh?=
SIMAMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nVemlEPTB;MkOuN|ghdk1?NYXzUIR5W0GQR1XS
DOHH-2NF7rN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDzd5RTUUN3ME2yN{41PSCwTR?=MmTaV2FPT0WU
IM-9M2TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;KNJlKSzVyPUKzMlU1KG6PNEDRXJlUSU6JRWK=
EC-GI-10M1TjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;OemE2UUN3ME2yOE4zOyCwTR?=MlfoV2FPT0WU
HDLM-2MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnqTWM2OD1{ND61OEBvVQ>?NGDTcFVUSU6JRWK=
LS-1034M3v2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTPS2V3UUN3ME2yOU44PSCwTR?=NXPvco1LW0GQR1XS
REHMonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3K4W2lEPTB;Mk[uOFEhdk1?MmjTV2FPT0WU
LU-165M3fGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ixZ2lEPTB;Mk[uO|Ihdk1?NH\JOmFUSU6JRWK=
NH-12M{fXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\QZpVLUUN3ME2yO{43PyCwTR?=NVfLWYt5W0GQR1XS
WSU-NHLMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJ6LkO5JI5ONYXWZ2o4W0GQR1XS
ECC4MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHmPWRmUUN3ME2yPE44QSCwTR?=NWnlN4VnW0GQR1XS
OCI-AML2MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJ7Lk[5JI5OM3;KUXNCVkeHUh?=
EW-3M3Pxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\WPIhuUUN3ME2zNE42QSCwTR?=NXjQ[oR6W0GQR1XS
NCI-H526MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTuTWM2OD1|Mj61OEBvVQ>?M333dnNCVkeHUh?=
NCI-H719NEjnb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LPO2lEPTB;M{SuN|Ehdk1?MmHoV2FPT0WU
KARPAS-422NG\rZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HlNmlEPTB;M{WuNFQhdk1?MlPJV2FPT0WU
SK-MEL-1M3jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHqwbFRKSzVyPUO1MlE4KG6PMkXYV2FPT0WU
ES3M4\ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHNclF5UUN3ME2zOU4yQSCwTR?=MVHTRW5ITVJ?
UACC-812MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DJNGlEPTB;M{WuOFQhdk1?M3\6UHNCVkeHUh?=
C8166NW\xbplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nxS2lEPTB;M{WuO{BvVQ>?MV;TRW5ITVJ?
MDA-MB-134-VIM{foS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPIOHhKSzVyPUO1Mlg4KG6PMX\TRW5ITVJ?
D-283MEDMmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nxWGlEPTB;M{euO|khdk1?M3n1cnNCVkeHUh?=
SHP-77MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTN6LkCzJI5ONED5NnhUSU6JRWK=
NCI-H2227NGj2eXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV30UIlXUUN3ME20NE41QSCwTR?=NWPPWYI3W0GQR1XS
SKM-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPBToJKSzVyPUSyMlY{KG6PMWTTRW5ITVJ?
L-428NEf6e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXFW2JnUUN3ME20N{45PiCwTR?=MlnHV2FPT0WU
RPMI-6666NV\0XHhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrJSINzUUN3ME20OU45QSCwTR?=NUPt[nd2W0GQR1XS
NCI-H716MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\DbVZKSzVyPUS4MlgyKG6PM4LDRXNCVkeHUh?=
DMS-79MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonZTWM2OD13MD63NUBvVQ>?MXzTRW5ITVJ?
RS4-11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\tOWlEPTB;NUCuPFghdk1?MVHTRW5ITVJ?
NCI-H720MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7BZolsUUN3ME21NU4yOSCwTR?=M1zZ[XNCVkeHUh?=
MC-CARMofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{frVmlEPTB;NUGuOVIhdk1?NWW4fWVkW0GQR1XS
TALL-1NF;KV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;VW2lEPTB;NUOuPVEhdk1?NFPSTXZUSU6JRWK=
NCI-N87MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlr6TWM2OD13ND6xPEBvVQ>?NWrzeZdpW0GQR1XS
P30-OHKNYnOSIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTV2Lk[xJI5ONX3Ob3JHW0GQR1XS
LP-1M1q4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzvbVQ5UUN3ME22NU4zQCCwTR?=M3LCVnNCVkeHUh?=
YTM2m1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTZzLkigcm0>NIfWboFUSU6JRWK=
MRK-nu-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XVR2lEPTB;NkGuPFIhdk1?MV7TRW5ITVJ?
BT-474MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTZ3IH7NNHn6VYdUSU6JRWK=
NCI-H322MMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\i[nRQUUN3ME22Ok4yOSCwTR?=NVvidm0zW0GQR1XS
NCI-H128MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPHTZlKSzVyPUe0Mlc4KG6PM3[wbnNCVkeHUh?=
KMS-12-PEMoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S1WWlEPTB;N{[uNlQhdk1?M1[3TnNCVkeHUh?=
KP-N-YSNGnw[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTd4Lke0JI5OMYDTRW5ITVJ?
ALL-PONX3pN2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{T0fmlEPTB;N{euOlYhdk1?M4Pvc3NCVkeHUh?=
EW-13NWjENW1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2P2fWlEPTB;N{euO|Yhdk1?Ml7YV2FPT0WU
EW-11MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fSSGlEPTB;N{iuOVIhdk1?MlTTV2FPT0WU
SK-N-FINFjoVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33WdGlEPTB;OECuNkBvVQ>?NEHrN5NUSU6JRWK=
CAL-148NWmwXJZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRThzLki0JI5ONFfhZ4xUSU6JRWK=
RLM{PvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDXXXhKSzVyPUi2MlA6KG6PNWn0T|dRW0GQR1XS
AM-38MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DVN2lEPTB;OEiuNFghdk1?NUXKU5dnW0GQR1XS
RH-1MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrKTWM2OD17OT64OUBvVQ>?M2q3[XNCVkeHUh?=
NCI-H1770NYXn[|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXQTWM2OD1zMEKuOFkhdk1?NIfobIhUSU6JRWK=
SIG-M5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXuTHdKSzVyPUGwOU4xPiCwTR?=MVXTRW5ITVJ?
GR-STM{\KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFqwZWZKSzVyPUGxN{4{PCCwTR?=NVfEOJlHW0GQR1XS
ST486NVjldZlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Hkd2lEPTB;MUG0MlA3KG6PMX3TRW5ITVJ?
NCI-H1650Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETGemVKSzVyPUGxOU4zQSCwTR?=M4rSUHNCVkeHUh?=
MHH-CALL-2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlO5TWM2OD1zMUWuO{BvVQ>?NFnyfndUSU6JRWK=
BV-173M2nHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITvd3ZKSzVyPUGyNk44OSCwTR?=M3PCUHNCVkeHUh?=
MC116NGHQXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX1XYNpUUN3ME2xOFgvQDVibl2=Mk\NV2FPT0WU
NCI-H524NHXiPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfoS4NKSzVyPUG1PU4yKG6PMYnTRW5ITVJ?
SCLC-21HNFzDZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4SzUGlEPTB;MUW5MlQyKG6PM3;zfHNCVkeHUh?=
NCI-H1304M1fIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Lud2lEPTB;MU[5MlIyKG6PNV\nfIliW0GQR1XS
NCI-H510AM3rVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;IbWlEPTB;MUi1MlM4KG6PNHT6copUSU6JRWK=
NCI-H209MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOwPZhKSzVyPUG5Ok42OiCwTR?=MXvTRW5ITVJ?
KM-H2MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LsOGlEPTB;MUm3MlA2KG6PMlv3V2FPT0WU
NCI-H1395MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkf5TWM2OD1{MUCuNVMhdk1?M33KcHNCVkeHUh?=
NCI-H1155NFPSeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn36TWM2OD1{M{CuN|Ihdk1?NYHiSoZZW0GQR1XS
COR-L279MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjYVWJKSzVyPUK1Nk4yPyCwTR?=MmT0V2FPT0WU
NCI-H1299NWDuO41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnhcJpZUUN3ME2yOlEvPzFibl2=Mn30V2FPT0WU
EW-22MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4n5dmlEPTB;Mk[zMlc2KG6PNF;JcFFUSU6JRWK=
SK-MEL-2MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJ6MT65JI5ONUfDeZRWW0GQR1XS
KASUMI-1MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XtVmlEPTB;MkizMlA2KG6PM1fhVHNCVkeHUh?=
NCI-H187NEXw[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS2UYhKSzVyPUK4O{4xQCCwTR?=Mn75V2FPT0WU
NCI-H2171NEjmWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkK5TWM2OD1{OEiuPVIhdk1?MVnTRW5ITVJ?
LNCaP-Clone-FGCNUfYV3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfTTWM2OD1{OUWuNlYhdk1?NWfU[VE2W0GQR1XS
NCI-H1522M4SwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTNyNz6wOUBvVQ>?M2XLWXNCVkeHUh?=
SCHNVvrOmhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLjTWM2OD1|MkKuNlIhdk1?MmS3V2FPT0WU
THP-1M2rP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojrTWM2OD1|MkKuOkBvVQ>?NF7VNpBUSU6JRWK=
SNU-C1NE\zWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{C4PGlEPTB;M{[yMlA6KG6PNWfsd4h3W0GQR1XS
CA46NGjrRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;FXWlEPTB;M{ezMlY{KG6PM2nZ[HNCVkeHUh?=
NCI-H1963M4\aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3aTWM2OD1|OE[uNVkhdk1?MlfmV2FPT0WU
DELNFy4Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fCbGlEPTB;M{mxMlI4KG6PMUPTRW5ITVJ?
TURNYe4TZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3GwVWlEPTB;M{m2MlYyKG6PNYC5[|NlW0GQR1XS
NCI-H226NWX0OoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFT0eHRKSzVyPUSwN{4zOyCwTR?=NUG3PXpXW0GQR1XS
COLO-668NFv5S2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DyPGlEPTB;NECzMlU4KG6PNFjMS5RUSU6JRWK=
CPC-NM{\2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjYTWM2OD12MEOuO|chdk1?MkXjV2FPT0WU
NCI-H889NWHGWVNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPoTWM2OD12NkGuPVIhdk1?NF\HPJlUSU6JRWK=
J-RT3-T3-5M1H1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTV|Mj61O{BvVQ>?MoPoV2FPT0WU
MSTO-211HMmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWqzVlM3UUN3ME21O|QvOjZibl2=NU\uVVBTW0GQR1XS
SCC-15M2nJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPaXYlKSzVyPU[2O{41PyCwTR?=NGrFfGpUSU6JRWK=
SUP-T1M17ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HZPWlEPTB;Nki2MlA1KG6PMUPTRW5ITVJ?
DMS-153MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTd2Nj64N{BvVQ>?NVu0N4MxW0GQR1XS
MS-1NHW3XllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEWxVYJKSzVyPUe1PU41OiCwTR?=NHXGdWxUSU6JRWK=
TC-YIKM2jRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zkUmlEPTB;N{ixMlAyKG6PM4TTZXNCVkeHUh?=
RPMI-8866MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnoO2tqUUN3ME2xNFA3NjJ6IN88US=>MUnTRW5ITVJ?
KY821MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLaTWM2OD1zMEO2MlA1KM7:TR?=MXnTRW5ITVJ?
P31-FUJMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrFN3dzUUN3ME2xNVEzNjd3IN88US=>MUPTRW5ITVJ?
COLO-824M{X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXpXHdKSzVyPUGyOlEvPzhizszNM3m1NHNCVkeHUh?=
U-698-MMk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVG0PVhmUUN3ME2yNlYzNjF3IN88US=>NGfYNGJUSU6JRWK=
TE-441-TMkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{e0OmlEPTB;MkWyNU44KM7:TR?=NUHDOYxoW0GQR1XS
IMR-5MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTN2MEmuOlIh|ryPMV;TRW5ITVJ?
NCI-H1838MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLhcodKSzVyPUSxPFYvOzJizszNMYXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02658396 Not yet recruiting Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National  ...more Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) December 2016 Phase 1
NCT02811978 Not yet recruiting Multiple Myeloma Janssen Research & Development, LLC September 2016 Phase 3
NCT02840539 Not yet recruiting Mantle Cell Lymphoma Seoul National University Hospital|Consortium for Improvi  ...more Seoul National University Hospital|Consortium for Improving Survival of Lymphoma August 2016 Phase 2
NCT02719613 Recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie July 2016 Phase 2
NCT02755597 Recruiting Relapsed/Refractory Multiple Myeloma AbbVie|Genentech, Inc. July 2016 Phase 3

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us